Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05324904
Other study ID # vitamin D3, acyclovir in warts
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2022
Est. completion date November 2023

Study information

Verified date April 2022
Source Assiut University
Contact maha m mostafa, MD
Phone +201158597040
Email mahamostafaali@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate and compare the efficacy and safety of intralesional acyclovir versus intralesional vitamin D3 in the treatment of plantar warts


Description:

Introduction Warts are common epidermal growths caused by various strains of human papillomavirus (HPV) affecting all age groups. They have an unsightly appearance and are mostly asymptomatic but sometimes may be painful as in the case of palmoplantar warts . Plantar warts is a clinical variant that occur on sole of the foot, most frequently over pressure points . It is estimated that 40% of population is infected with HPV, and in 7% to 12%, a wart develops . Plantar warts exhibit an annual incidence of 14% in the general population . Sixty-five percent to 78% of cutaneous warts have been shown to regress within 2 years . In persons older than 12 years, the rate of spontaneous regression significantly decreases . Variable therapeutic options are available for treating warts, with none considered a gold standard. Primary treatments include topical salicylic acid, topical imiquimod, topical 5-fluorouracil, cryotherapy, excision, electrocautry and laser vaporization . Vitamin D is a fat-soluble steroid prohormone that has wide range of biological actions e.g. inhibition of cellular proliferation, induction of terminal differentiation, and inhibition of angiogenesis. It also stimulates macrophages and cathelicidin production . Recently, several studies have demonstrated the efficacy of intralesional vitamin D in treatment of warts, as well as recalcitrant lesions, with clearance rates of 72.5%-90% . Acyclovir is a synthetic purine nucleoside analogue with activity against some viruses as herpes simplex and varicella-zoster virus. Acyclovir uses viral thymidine kinase to convert to its active form, acyclovir triphosphate. Through this mechanism of utilizing viral thymidine kinase, acyclovir specifically targets viral DNA preventing its replication in the host. Previously, few studies and case reports documented the clearance of warts, some were unresponsive to prior treatment, with both topical and oral use of acyclovir . A recent study has evaluated the efficacy of intralesional acyclovir versus intralesional saline in treatment of warts and reported complete clearance rate of 52.6% and a partial response of 16.7% for acyclovir with a statistically significant difference from saline (0% complete clearance) .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 44
Est. completion date November 2023
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 12 Years to 70 Years
Eligibility Inclusion Criteria: - Adult participants of both sex with plantar warts will be included in the study Exclusion Criteria: - - Children < 12 years. - Pregnant and lactating women. - Receiving any treatment for warts within 1 month before the study. - Systemic antiviral medication. - Previous history of vitamin D or acyclovir hypersensitivity. - Vitamin D supplementation. - Concurrent other skin disorders. - Immunosuppressive disorders or receiving immunosuppressive drugs. - Receiving drugs that may alter vitamin D level including prednisone, orlistat, phenytoin and thiazide diuretics.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vitamin D
- Vitamin D The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML, Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts > 10 mm need multiple injections at different sites) Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions
acyclovir
-Acyclovir Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution. After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions

Locations

Country Name City State
Egypt Assuit University Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary complete healing rate Main outcome variable is the complete healing rate among planter warts patients treated with intralesional vitamin D3 compared to those by Intralesional acyclovir 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05592041 - Studying of Natural Constituents' Treatment of Plantar Warts Early Phase 1
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Recruiting NCT06261684 - Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial. Phase 2/Phase 3
Not yet recruiting NCT05057663 - Intralesional Treatment of Plantar Wart N/A
Recruiting NCT02151630 - Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Phase 2/Phase 3
Withdrawn NCT04823845 - Plantar Wart Treatment Using Adapalene Gel Early Phase 1
Completed NCT05588999 - Comparative Study Between Treatment With Cryotherapy Alone Versus Cryotherapy Plus Salicylic Acid Dressing for Planter Warts Phase 1
Completed NCT01536834 - Safety & Performance Study of Verruca Treatment Device N/A
Recruiting NCT05488860 - Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases N/A
Recruiting NCT05520658 - Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts N/A
Not yet recruiting NCT04654091 - Cryotherapy VS. Nitric-zinc Complex in the Treatment of Plantar Warts. N/A
Not yet recruiting NCT05599971 - Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts N/A
Not yet recruiting NCT05198180 - Treatment of Plantar Warts Phase 3
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Recruiting NCT03977753 - Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts Phase 4
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4